Quarterly report · Q2
2112.TEDINET S100PGCP
Period2022-04-01 → 2022-09-30
Filed2022-11-04
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥25.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥274m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥454m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥244m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥906m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥389m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥244m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥389m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥138m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥609m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥233m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥138m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥233m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥25.2bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥26.1bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥26.7bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥15.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥10.4bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.0bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥104m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥210m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥172m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥711m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥482m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥948m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥5.1 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.14 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.43 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.61 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.55 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥67m |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥59m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8m |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥577m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥925m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥891m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥34m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥238m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥13m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥582m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥55m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥851m |
| Otherother segments | revenue | 2021-04-01 → 2021-09-30 | ¥66m |
| Otherother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥58m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| Otherother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥30m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥50m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥50m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥586m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥939m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥910m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥28m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥264m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥11.3bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.3bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥14m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥745m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥12.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥50m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments of loans receivable inv cf | Prior1YTDDuration | -450000000 | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -470000000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 431000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 436000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -0 | JPY |
| Other net inv cf | CurrentYTDDuration | -3000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -482000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -172000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | -350000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 477000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -940000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -1040000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -135000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -135000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -948000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -1175000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 0 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 11000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -1219000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -1233000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 4897000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 3533000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 3677000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 2300000000 | JPY |
| Products warehouse and transportation expenses sga | Prior1YTDDuration | 485000000 | JPY |
| Products warehouse and transportation expenses sga | CurrentYTDDuration | 479000000 | JPY |
| Sales promotion expenses sga | Prior1YTDDuration | 6000000 | JPY |
| Sales promotion expenses sga | CurrentYTDDuration | 6000000 | JPY |
| Payrolls allowances and compensation sga | Prior1YTDDuration | 228000000 | JPY |
| Payrolls allowances and compensation sga | CurrentYTDDuration | 223000000 | JPY |
| Provision for compensation sga | Prior1YTDDuration | 51000000 | JPY |
| Provision for compensation sga | CurrentYTDDuration | 48000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 17000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 11000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 11276000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 910000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 58000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 12246000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 12246000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 28000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 8000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 50000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -50000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |